SAB Biotherapeutics Inc. (SABS) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SABS scores 37 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:

• Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -27.4% and an FCF yield of -15.55%. For a prospective investor, the core cash-generation test is currently failing; the business is consuming capital rather than producing it relative to its market value.
• Whale / 13F Flow: 8 / 20. Per the Roarable RQD rating, institutional accumulation and options positioning are scored weak. The source data contains no holder detail (see Analyst View section), so this score cannot be independently traced to specific filings.
• Insider Conviction: 4 / 20. Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow is scored low. Investors should read this as limited evidence of insider buying conviction, though the underlying transactions are not itemized in the source data.
• Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector sensitivity profile scored modestly. The stock is therefore roughly market-correlated in volatility, with no additional regime tailwind identified in the data.
• Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 7.07, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar: the Altman Z reading is high, which in the rating's framework points to relative solvency resilience, while the Piotroski score signals weak fundamental quality across its nine tests.

Taken together, the rating frames SABS as a company whose balance sheet is comparatively sturdy but whose cash generation and flow indicators are weak. The upside case rests on the balance sheet giving management runway; the valuation tradeoff is that a P/E of 22.1 (TTM) sits against negative ROIC and negative FCF yield, meaning the earnings multiple is not being supported by operating cash returns. Second-order risk is that continued cash burn could erode the balance-sheet strength the forensic pillar currently credits.

SAB Biotherapeutics Inc. (SABS) is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances). Per the company profile, it has a market capitalization of $0.3B. Per the recent news wire, the company's pipeline activity includes SAB-142, which received FDA Fast Track Designation in Type 1 Diabetes. The source data does not describe its customers or detail how it generates revenue, and reported revenue is $0.0M for FY 2025.

Per the SEC financials, operating losses persisted across all three reported years, and operating margin is recorded as 0% in market data. Gross, operating, and net margins are all listed as 0%, and ROIC stands at -27.4%. The FY 2025 net income of $13.3M contrasts with an operating loss of $-49.0M, a divergence the source data does not explain. Per the Roarable RQD rating, the Altman Z-Score is 7.07 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5; reported cash fell from $10.5M (FY 2025) to $8.9M (FY 2024) in the prior year column, and FY 2025 cash is the latest figure shown.

• Clinical catalyst: An item flagged CATALYST (Simply Wall St) reports on investment positioning; the most material clinical headline is that SAB-142 received FDA Fast Track Designation in Type 1 Diabetes (Yahoo Finance). Fast Track is a regulatory designation; the source data does not state its financial impact.
• Trial progress: A Yahoo Finance item highlights diabetes trial progress and the human antibody platform.
• Investor visibility: A Stock Titan item notes the CEO will take part in a fireside chat at a New York healthcare conference.
• Earnings commentary: A TradingView item covers Q2 earnings call highlights.
• Risk watch: The news items are generally market-wire coverage without quantified results; no specific earnings figures from the call are included in the source data.

Proprietary signals: Per the Butterfly Supply-Chain Graph, the proprietary signals list is empty.

• What drove the FY 2025 net income of $13.3M when operating income was $-49.0M, and is that gain recurring?
• What is the company's cash runway given FY 2025 cash of $10.5M against FCF of $-45.7M?
• What is the debt position, since the debt field is N/A for every reported period despite a Debt/Equity figure of 0.5?
• What were the specific results and guidance from the Q2 earnings call?
• What is the revenue model behind the reported $0.0M FY 2025 and $1.3M FY 2024 revenue figures?